MEK
Mitogen-activated protein kinase kinase (MEK), primarily represented by MEK1 (MAP2K1) and MEK2 (MAP2K2), is a dual-specificity protein kinase that phosphorylates and activates extracellular signal-regulated kinases ERK1 and ERK2, thereby functioning as a central signaling relay within the MAPK/ERK cascade[1][2]. MEK operates downstream of RAS and RAF kinases and transduces extracellular and intracellular signals into programs controlling cell proliferation, differentiation, survival, transcriptional regulation, and development[2][3][4]. Mechanistically, RAF-mediated activation of MEK enables phosphorylation of ERK proteins at the conserved Thr-Glu-Tyr motif, leading to signal propagation through the canonical MAPK pathway[2][5]. Aberrant activation of MEK signaling has been associated with multiple human diseases, including melanoma, lung cancer, ovarian cancer, leukemia, lymphoma, and developmental disorders linked to dysregulated RAS/MAPK signaling[2][6][7]. Compared with other MAP2K family members that regulate the p38 or JNK pathways, MEK1 and MEK2 function specifically within the ERK signaling branch, providing pathway selectivity and making them key experimental targets for dissecting MAPK-dependent biological responses[1]. For experimental applications, pharmacological MEK inhibitors including trametinib, selumetinib, cobimetinib, binimetinib, mirdametinib, and avutometinib are widely used to suppress ERK activation and investigate MEK-dependent signaling mechanisms in cancer and developmental biology models[2].
-
MEK Related Products (154)
Related Products (154)
-
Antibodies (2)
-
MAP2K1 L115P Recombinant Human Active Protein Kinase
0 ImagesCat. No.: HY-E70842MAP2K1 (also known as MEK1) is downstream of the RAF family and activation results in ERK1/2 activation. Activating mutations in MAP2K1 have been reported almost exclusively in exons 1 and 2 in both hematologic malignancies. MAP2K1 L115P is a mutant of MAP2K1. MAP2K1 L115P Recombinant Human Active Protein Kinase is a recombinant MAP2K1 L115P protein that can be used to study MAP2K1 L115P-related functions.
-
Cobimetinib-13C6 racemate
0 ImagesCat. No.: HY-13078SSynonyms: GDC-0973-13C6 racemate; XL518-13C6 racemateCobimetinib-13C6 (GDC-0973-13C6; XL518-13C6) racemate is the deuterium labeled Cobimetinib (racemate) (HY-13078). Cobimetinib racemate (GDC-0973 racemate; XL518 racemate) is the racemate of Cobimetinib. Cobimetinib is a potent and selective MEK inhibitor.
-
Ferroptosis inducer-7
0 ImagesCat. No.: HY-172803CAS No.: 2723569-00-2Ferroptosis inducer-7 is an orally active and selective ferroptosis inducer via inositol 1,4,5-trisphosphate receptor (IP3R)/calcium release-activated calcium channel protein (ORAI). Ferroptosis inducer-7 exhibits a notable effect in alleviating anemia symptoms, suppressing bone marrow CTLs activation, and improving hematopoietic function in immune-mediated bone marrow failure. Ferroptosis inducer-7 can be studied in research for aplastic anemia.
-
PQ-1
0 ImagesCat. No.: HY-14584CAS No.: 955995-48-9PQ-1 is a gap junction enhancer.
-
Map2k2 Mouse Pre-designed siRNA Set A
0 ImagesCat. No.: HY-RS08037Map2k2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Map2k2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
-
MAP2K2 Human Pre-designed siRNA Set A
0 ImagesCat. No.: HY-RS08036MAP2K2 Human Pre-designed siRNA Set A contains three designed siRNAs for MAP2K2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
-
MO-2097
0 ImagesCat. No.: HY-N13009CAS No.: 2744300-63-6MO-2097 is a RAF-1/HIF-1α inhibitor. MO-2097 induces RAF-1 destabilization, leading to a reduction in EMT-associated transcription factors and mesenchymal markers. MO-2097 inhibits HIF-1a protein expression mediated by hnRNPA2B1 under hypoxic and mimetic hypoxia. MO-2097 induces mitochondrial ROS, which leads to apoptosis in cells. MO-2097 effectively suppresses colorectal cancer metastasis by inhibiting the RAF/MEK/ERK signaling pathway. MO-2097 attenuates tumor growth in a xenograft HCT116 cell mouse model. MO-2097 can be used for the study of colorectal cancer.
-
BAY-866
0 ImagesCat. No.: HY-126180CAS No.: 1836185-18-2
-
BRAFV600E/JNK-IN-1
0 ImagesCat. No.: HY-173153BRAFV600E/JNK-IN-1 (Compound 14c) is an inhibitor of JNK1, JNK2, JNK3 and BRAFV600E, with IC50 values of 0.51 μM, 0.53 μM, 1.02 μM and 0.009 μM, respectively. BRAFV600E/JNK-IN-1 can inhibit the phosphorylation of MEK1/2 and ERK1/2. In addition, BRAFV600E/JNK-IN-1 can inhibit tumor cell proliferation, NO release and PGE2 production, and has anti-tumor and anti-inflammatory activities.
-
SMK-17
0 ImagesCat. No.: HY-12447CAS No.: 765958-29-0
-
Map2k2 Rat Pre-designed siRNA Set A
0 ImagesCat. No.: HY-RS08038Map2k2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Map2k2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
-
Binimetinib-d3
0 ImagesCat. No.: HY-15202S1CAS No.: 2890696-59-8Synonyms: MEK162-d3; ARRY-162-d3; ARRY-438162-d3Binimetinib-d3 (MEK162-d3) is deuterium labeled Binimetinib. Binimetinib (MEK162) is an oral and selective MEK1/2 inhibitor. Binimetinib (MEK162) inhibits MEK with an IC50 of 12 nM.
-
(R)-PD 0325901CL
0 ImagesCat. No.: HY-10508CAS No.: 1003216-77-0(R)-PD 0325901CL is an isomer of PD 0325901CL. PD 0325901CL is a selective inhibitor of mitogen-activated protein kinase kinase (MEK) involved in cancer research. PD 0325901CL inhibits the growth of cancer cells in vitro and in vivo.
-
X-370
0 ImagesCat. No.: HY-12482CAS No.: 1280725-80-5X-370 is a PI3Kδ inhibitor (IC50 = 7 nM). X-370 inhibits the survival of leukemia cells, inducing G1 arrest and apoptosis. X-370 blocks PDK1 binding and phosphorylation of MEK1/2, eliminating Akt and Erk1/2 signaling. X-370 can be used in research on B-cell acute lymphoblastic leukemia (B-ALL).
-
Map2k5 Mouse Pre-designed siRNA Set A
0 ImagesCat. No.: HY-RS08042Map2k5 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Map2k5 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
-
PD-254552
0 ImagesCat. No.: HY-118626CAS No.: 284030-47-3PD-254552 is a MEK inhibitor. PD-254552 exhibits hepatotoxicity and gastrointestinal toxicity in mice.
-
MAP2K5 Human Pre-designed siRNA Set A
0 ImagesCat. No.: HY-RS08041MAP2K5 Human Pre-designed siRNA Set A contains three designed siRNAs for MAP2K5 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
-
Lidocaine hydrochloride hydrate (Standard)
0 ImagesSynonyms: Lignocaine hydrochloride hydrate (Standard)Lidocaine (hydrochloride hydrate) (Standard) is the analytical standard of Lidocaine (hydrochloride hydrate). This product is intended for research and analytical applications. Lidocaine (Lignocaine) hydrochloride hydrate inhibits sodium channels involving complex voltage and using dependence. Lidocaine hydrochloride hydrate decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine hydrochloride hydrate is an amide derivative and has potential for the research of ventricular arrhythmia.
-
MEK-IN-4
0 ImagesCat. No.: HY-137881CAS No.: 297744-42-4MEK-IN-4 is a MEK inhibitor. MEK-IN-4 can be used for the research of inflammatory disorders and cancers.
-
Trametinib-13C,d3
0 ImagesCat. No.: HY-10999S2CAS No.: 2712126-59-3Synonyms: GSK1120212-13C,d3; JTP-74057-13C,d3Trametinib-13C,d3 is the 13C- and deuterium labeled Trametinib. Trametinib (GSK1120212; JTP-74057) is an orally active MEK inhibitor that inhibits MEK1 and MEK2 with IC50s of about 2 nM. Trametinib activates autophagy and induces apoptosis.
